Abstract Library

#2940 Avelumab in Unresectable/Metastatic, Progressive, Poorly Differentiated, Grade 3 Neuroendocrine Carcinomas (NECs)

Introduction: Poorly differentiated, G3 NECs are associated with poor outcomes and have no effective treatment options apart from cytotoxic chemotherapy.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Rodriguez-Freixinos V

Authors: Rodriguez-Freixinos V, Chan D, Doherty M, Wasson K, Iscoe N,

Keywords: Poorly differentiated, G3 NECs, Avelumab, Immunotherapy,

#2244 Late Metastasis of Pancreatic Gastrinoma

Introduction: Pancreatic gastrinoma associated with MEN1 syndrome are rare and aggressive tumours, presenting a high risk of liver metastasis, and a poor prognosis.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Muñoz de Nova J, Di Martino M, Martín Pérez E, Sampedro-Nuñez M, de la Hoz Rodríguez �,

Keywords: gastrinoma, liver metastasis, MEN1, c.604A>C/p.T202P,

#1906 High Prevalence of the c.1546delC Germline Mutation in MEN1 Pancreatic Neuroendocrine Tumors

Introduction: Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant disease predisposing to pancreatic neuroendocrine neoplasms (NENs). Even though its genetics is relatively well known, specific phenotype-genotype correlations remain unproven at present. The Region of Murcia in southeast Spain is one of the areas with the highest incidence of MEN1

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Marín Zafra G

Authors: Marín Zafra G, Carmona-Bayonas A, Segura Luque P, Rodríguez González J, Tebar Massó J,

Keywords: MEN1 genetics,

#1136 Small Bowel Neuroendocrine Tumors (NET): Relationship Between Radiologic Features, Functionality and Ki-67 Classification.

Introduction: Since small bowel NETs are usually small tumors, detection and characterization of metastatic affection plays an important role.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Rodriguez-Laval V

Authors: Rodriguez-Laval V, Tischer E, Pavel M, Wiedenmann B, Hamm B,

Keywords: desmoplastic,CT,NET,carcinoid,

#1026 Systemic Therapy in Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) and Ki Index 5-10%

Introduction: Phase III trials of sunitinib, everolimus and octreotide lar confirmed that these drugs improved progression-free survival (PFS) in well-differentiated PNET, low/intermediate grade pNET and well-differentiated midgut NETs, respectively. CLARINET is the 1st phase III study that showed PFS benefit of SSA, lanreotide, in both P- and midgut NET and in Ki-67 5-10%.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Jiménez-Fonseca P, Carmona A, Faez L, Solis P, Rodriguez D,

Keywords: Ki-67, pancreatic neuroendocrine tumor, systemic therapy,